title: Newly diagnosed breast cancer in a patient receiving imatinib mesylate.
abstract: Imatinib mesylate is the standard treatment of chronic myeloid leukemia (CML). Despite imatinib is being used in the treatment of other malignancies as well, its potential role on de novo tumor growth is not known. Secondary malignancies are rarely seen in patients with CML and particularly in those receiving imatinib. Here, we present a CML patient taking imatinib therapy that was diagnosed to have breast cancer and received adjuvant chemo-and radiotherapy with imatinib. We tried to explain co-occurrence of these rare events by probable pathogenetic mechanisms.
authors.forename: Isik
authors.initials: I
authors.lastname: Kaygusuz-Atagunduz
authors.affiliation: Department of Internal Medicine, Divisions of Hematology, Marmara University Hospital, Istanbul, Turkey.
authors.forename: Tayfur
authors.initials: T
authors.lastname: Toptas
authors.forename: Fulden
authors.initials: F
authors.lastname: Yumuk
authors.forename: Tulin
authors.initials: T
authors.lastname: Firatli-Tuglular
authors.forename: Mahmut
authors.initials: M
authors.lastname: Bayik
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000150:complications* / Q000209:etiology*; D017024:Chemotherapy, Adjuvant; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate / Q000009:adverse effects* / Q000627:therapeutic use; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000150:complications* / Q000188:drug therapy*; D008408:Mastectomy; D008875:Middle Aged; D009362:Neoplasm Metastasis; D011505:Protein-Tyrosine Kinases / Q000378:metabolism; D011878:Radiotherapy / Q000379:methods
chemical_list: D000970:Antineoplastic Agents; D000068877:Imatinib Mesylate; D011505:Protein-Tyrosine Kinases